![Louis J. Arcudi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Louis J. Arcudi
President chez
Millendo Therapeutics US, Inc.
Profil
Louis J.
Arcudi is Co-President & Secretary at Millendo Therapeutics US, Inc. Formerly, Mr. Arcudi was President, Chief Executive Officer & Director at Millendo Therapeutics, Inc. in 2021.
From 2015 to 2018, served as CFO, Treasurer & Chief Accounting Officer at Idera Pharmaceuticals, Inc. From 2002 to 2007, held the position of Treasurer, VP-Administration & Finance at Peptimmune, Inc. Between 2000 and 2003, was Senior Director-Finance & Administration at Genzyme Molecular Oncology.
In 2003, was Senior Director-Finance Business Planning at Genzyme Corp.
Also worked as Controller at Cognex Corp.
Education includes an undergraduate degree from Southern New Hampshire University in 1982 and an MBA from Bryant University in 1987.
Postes actifs de Louis J. Arcudi
| Sociétés | Poste | Début |
|---|---|---|
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company which develops a novel treatment for adrenal cancer | President | - |
Anciens postes connus de Louis J. Arcudi
| Sociétés | Poste | Fin |
|---|---|---|
| MILLENDO THERAPEUTICS | Directeur Général | 25/06/2021 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Directeur Financier/CFO | 31/10/2018 |
Peptimmune, Inc.
 Peptimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceutical products | Directeur Financier/CFO | 01/12/2007 |
Genzyme Molecular Oncology
 Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Develops novel cancer therapeutics and diagnostics | Directeur Financier/CFO | 01/01/2003 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Directeur Financier/CFO | 01/01/2003 |
Formation de Louis J. Arcudi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
60
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Cognex Corp.
 Cognex Corp. Electronic Equipment/InstrumentsElectronic Technology Develops, manufactures and markets machine vision computer systems | Electronic Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company which develops a novel treatment for adrenal cancer | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceutical products | Health Technology |
Southern New Hampshire University
 Southern New Hampshire University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Develops novel cancer therapeutics and diagnostics | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
